Agenda
3:00 PM - 3:30 PM   Registration and Networking
3:30 PM - 5:00 PM   Industry Panel
5:00 PM - 6:30 PM   Networking Reception

Modern evolution theory suggests only the fittest will survive; in the business world, we know this to be fact. Find out what it takes to prepare your company for survival. Join this panel to hear survival tips from VC investors, big pharma, and what they look for in an investment.

Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.

Speakers

Peter McWilliams, Managing Director, Sanderling Ventures

Bob Ward, Principal, Kaiser Permanente Ventures

Mark Barrett, Director, Business Development, Johnson & Johnson

Mark Schwartz, PhD, former President & CEO, Bayhill Therapeutics

Lead Facilitator: Scott M. Iyama, Corporate Lawyer, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LLP

Speakers Bios
Peter McWilliams, Managing Director, Sanderling Ventures
Peter McWilliams is a Principal with Sanderling Ventures and has more than 15 years experience in biomedical research and management. He works actively with Sanderling portfolio companies in the role of Chairman, Director, CEO and member of the management team. Portfolio companies include Actimis Pharmaceuticals (sold to Boehringer Ingelheim), Trinity Biosystems, Artielle Immunotherapeutics, Harkness Pharmaceuticals, Calcimedica and Cylene Pharmaceuticals. Prior to joining Sanderling, Dr. McWilliams worked at Genentech where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in clinical and pre-clinical development and was the Commercial Team Leader for Avastin. Prior to that he was an Associate with Booz.Allen & Hamilton in San Francisco where he focused on projects for major US and International life science companies. Prior to that he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics, where he helped to set up and establish their US operations prior to their successful IPO on the London Stock Exchange. Dr. McWilliams received an M.B.A. from Columbia Business School, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. and M.A. in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University.
Bob Ward, Principal, Kaiser Permanente Ventures
Bob was instrumental in establishing the Kaiser Permanente Venture Fund in 2000 and is responsible for managing the pipeline of new venture prospects, as well as leading investment evaluations and financing decisions. He is a manager or board observer for several portfolio companies and targets investments in imaging, lab/diagnostics, women's health and related therapeutics/devices. Prior to joining Kaiser Permanente in 1997, Bob pursued a career in banking at Wells Fargo and other financial institutions with responsibilities in treasury operations, performance planning/metrics, incentive compensation and finance training. He holds a MBA in Finance from the University of California at Berkeley and a Bachelor's Degree in Economics from the University of Washington. Bob has completed the executive management leadership program at the University of North Carolina and Venture Capital Institute graduate programs.
Mark Barrett, Director, Business Development, Johnson & Johnson
Mr. Barrett has 15 years of experience in business development, corporate strategy, and research in pharmaceutical and biotech companies and research institutions. Since 2002, he has been a member of Johnson & Johnson’s pharmaceutical business development group with responsibility for leadership and execution of global transactions including commercial and clinical stage product and company acquisitions and R&D collaborations across therapeutic and technology areas. Mr. Barrett’s areas of expertise include commercial and strategic assessments, managing cross functional diligence and deal teams, and structuring and negotiating transactions. Mr. Barrett holds an MBA from UC Berkeley and a BS from Duke University.
Mark W. Schwartz, Ph.D., former President & CEO, Bayhill Therapeutics
Mark W. Schwartz, Ph.D. has served as Bayhill Therapeutics President & Chief Executive Officer from March 2004 to September 2009. From 2003 to 2004, Dr. Schwartz was Managing Director of Life Sciences at Arizona Technology Enterprises. From 2001 to 2003, Dr. Schwartz was Chief Executive Officer and President of Calyx Therapeutics Inc. From 1999 to 2001, Dr. Schwartz was Chief Commercial Officer of Trega BioSciences, Inc., and helped lead the merger of Trega with Lion Biosciences. From 1997 to 1998, Dr. Schwartz held senior management positions at Synteni, Inc. and Incyte Genomics, Inc., which acquired Synteni, Inc. in 1998. From 1994 to 1997, Dr. Schwartz held senior management positions at Tripos, Inc., where he led the development of the combinatorial chemistry business. From 1989 to 1994, Dr. Schwartz held marketing positions at Biosym Technologies, Inc., which was acquired by Corning Incorporated in 1992, and Applied Biosystems Inc. From 1983 to 1989 Dr. Schwartz held research and development as well as marketing positions in the diagnostics business of E.I. du Pont de Nemours and Company. Dr. Schwartz received a B.A. in Chemistry from Grinnell College and a Ph.D. in Biochemistry from Arizona State University.
Facilitator: Scott Iyama, Corporate Lawyer, Orrick, Herrington & Sutcliffe LLP
Scott Iyama, a corporate associate in Orrick's Silicon Valley office, is a member of the Emerging Companies Group, which advises emerging companies and venture capital firms. Mr. Iyama's practice focuses on the representation of emerging growth life science and high tech companies, as well as public offerings, private venture financings and technology transactions.